Haleon plc (HLN) 10-Year Financial Performance & Capital Metrics

HLN • • Industrial / General

HealthcareSpecialty & Generic PharmaConsumer HealthcareOTC Medications

AboutHaleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.Show more

Revenue $11.23B -0.6%
EBITDA $2.4B +4.2%
Net Income $1.44B +37.5%
EPS (Diluted) 0.32 +33.3%
Gross Margin 61.85% +0.4%
EBITDA Margin 21.38% +4.8%
Operating Margin 19.64% +11.2%
Net Margin 12.84% +38.3%
ROE 8.75% +38.4%
ROIC 6.72% +15.2%
Debt/Equity 0.62 +10.2%
Interest Coverage 5.60 +16.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y profit CAGR of 17.1%
✓FCF machine: 18.3% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Healthy 5Y average net margin of 11.6%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y5.78%

3Y5.58%

TTM62.05%

Profit (Net Income) CAGR

10Y-

5Y17.1%

3Y1.23%

TTM49.48%

EPS CAGR

10Y-

5Y17.98%

3Y2.17%

TTM52.45%

ROCE

10Y Avg5.63%

5Y Avg6.19%

3Y Avg6.77%

Latest7.62%

Peer Comparison

OTC Medications

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
HLNHaleon plc	43.51B	9.77	30.53	-0.61%	11.72%	16.31%	4.71%	0.62
UPCUniverse Pharmaceuticals Inc.	2.59M	4.59	-0.00	-28.74%	-37.94%	-31.64%		0.18
PRPHProPhase Labs, Inc.	711.94K	0.17	-0.07	-84.75%	-38.72%	-6.08%		3.34
COSMCosmos Health Inc.	20.24M	0.54	-0.46	1.97%	-31.01%	-80.15%		0.48
PRGOPerrigo Company plc	2.09B	15.17	-12.14	-6.06%	-1.21%	-1.17%	11.72%	0.84

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	8.48B	9.89B	9.54B	10.86B	11.3B	11.23B
Revenue Growth %	-	0.17%	-0.04%	0.14%	0.04%	-0.01%
Cost of Goods Sold+	3.68B	3.98B	3.6B	4.28B	4.34B	4.29B
COGS % of Revenue	0.43%	0.4%	0.38%	0.39%	0.38%	0.38%
Gross Profit+	4.8B	5.91B	5.95B	6.58B	6.96B	6.95B
Gross Margin %	0.57%	0.6%	0.62%	0.61%	0.62%	0.62%
Gross Profit Growth %	-	0.23%	0.01%	0.11%	0.06%	-0%
Operating Expenses+	3.9B	4.31B	4.31B	4.75B	4.96B	4.74B
OpEx % of Revenue	0.46%	0.44%	0.45%	0.44%	0.44%	0.42%
Selling, General & Admin	3.6B	4.22B	3.79B	4.04B	4.29B	4.33B
SG&A % of Revenue	0.42%	0.43%	0.4%	0.37%	0.38%	0.39%
Research & Development	292M	304M	257M	300M	311M	298M
R&D % of Revenue	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%
Other Operating Expenses	17M	-212M	262M	415M	366M	111M
Operating Income+	897M	1.6B	1.64B	1.82B	2B	2.21B
Operating Margin %	0.11%	0.16%	0.17%	0.17%	0.18%	0.2%
Operating Income Growth %	-	0.78%	0.03%	0.11%	0.09%	0.11%
EBITDA+	1.16B	1.9B	1.91B	2.11B	2.31B	2.4B
EBITDA Margin %	0.14%	0.19%	0.2%	0.19%	0.2%	0.21%
EBITDA Growth %	-	0.64%	0%	0.11%	0.09%	0.04%
D&A (Non-Cash Add-back)	260M	305M	268M	287M	309M	196M
EBIT	912M	1.61B	1.94B	1.9B	2.04B	2.32B
Net Interest Income+	-10M	-13M	-3M	-220M	-400M	-339M
Interest Income	24M	0	13M	62M	14M	55M
Interest Expense	26M	15M	16M	278M	414M	394M
Other Income/Expense	-11M	-7M	-2M	-207M	-368M	-296M
Pretax Income+	886M	1.59B	1.64B	1.62B	1.63B	1.91B
Pretax Margin %	0.1%	0.16%	0.17%	0.15%	0.14%	0.17%
Income Tax+	199M	410M	197M	499M	517M	435M
Effective Tax Rate %	0.74%	0.72%	0.85%	0.66%	0.64%	0.75%
Net Income+	655M	1.15B	1.39B	1.06B	1.05B	1.44B
Net Margin %	0.08%	0.12%	0.15%	0.1%	0.09%	0.13%
Net Income Growth %	-	0.75%	0.21%	-0.24%	-0.01%	0.37%
Net Income (Continuing)	687M	1.18B	1.44B	1.12B	1.11B	1.48B
Discontinued Operations	0	0	0	0	0	0
Minority Interest	91M	111M	125M	126M	123M	58M
EPS (Diluted)+	0.14	0.24	0.30	0.24	0.24	0.32
EPS Growth %	-	0.71%	0.25%	-0.2%	0%	0.33%
EPS (Basic)	0.14	0.24	0.30	0.24	0.24	0.32
Diluted Shares Outstanding	4.62B	4.62B	4.62B	4.62B	4.63B	4.59B
Basic Shares Outstanding	4.62B	4.62B	4.62B	4.62B	4.63B	4.57B
Dividend Payout Ratio	1.76%	2.07%	0.83%	2.53%	0.37%	0.4%

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.81B	5.01B	5.25B	4.06B	4.82B	5.72B
Cash & Short-Term Investments	340M	334M	414M	684M	1.04B	2.25B
Cash Only	340M	334M	414M	684M	1.04B	2.19B
Short-Term Investments	0	0	0	0	0	55M
Accounts Receivable	3.99B	1.35B	3.83B	1.49B	1.35B	1.9B
Days Sales Outstanding	171.91	49.74	146.27	49.99	43.66	61.87
Inventory	1.21B	949M	951M	1.35B	1.41B	1.19B
Days Inventory Outstanding	120.18	86.99	96.55	114.93	118.39	101.37
Other Current Assets	237M	2.32B	5M	434M	907M	223M
Total Non-Current Assets+	29.9B	29.12B	29.2B	30.76B	29.24B	28.6B
Property, Plant & Equipment	1.62B	1.6B	1.66B	1.9B	1.9B	1.92B
Fixed Asset Turnover	5.23x	6.17x	5.74x	5.72x	5.94x	5.85x
Goodwill	8.17B	8.27B	8.25B	8.4B	8.32B	8.2B
Intangible Assets	19.84B	18.95B	18.95B	20.04B	18.54B	18.01B
Long-Term Investments	3M	0	23M	44M	65M	82M
Other Non-Current Assets	10M	51M	8M	157M	415M	383M
Total Assets+	35.71B	34.13B	34.45B	34.81B	34.05B	34.31B
Asset Turnover	0.24x	0.29x	0.28x	0.31x	0.33x	0.33x
Asset Growth %	-	-0.04%	0.01%	0.01%	-0.02%	0.01%
Total Current Liabilities+	4.27B	4.01B	4.24B	4.37B	4.64B	5.81B
Accounts Payable	1.9B	1.83B	1.58B	1.83B	1.85B	1.97B
Days Payables Outstanding	188.36	167.47	160.32	156.45	155.97	168.06
Short-Term Debt	481M	348M	874M	393M	608M	1.44B
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0
Other Current Liabilities	913M	958M	1.43B	1.61B	1.57B	693M
Current Ratio	1.36x	1.25x	1.24x	0.93x	1.04x	0.98x
Quick Ratio	1.08x	1.01x	1.01x	0.62x	0.73x	0.78x
Cash Conversion Cycle	103.73	-30.74	82.51	8.46	6.08	-4.83
Total Non-Current Liabilities+	4.03B	3.89B	3.73B	13.99B	12.69B	12.28B
Long-Term Debt	0	0	0	9.89B	8.71B	8.54B
Capital Lease Obligations	121M	105M	87M	117M	89M	73M
Deferred Tax Liabilities	3.51B	0	3.36B	3.6B	3.49B	3.35B
Other Non-Current Liabilities	0	3.79B	0	384M	424M	311M
Total Liabilities	8.3B	7.91B	7.97B	18.36B	17.33B	18.09B
Total Debt+	642M	487M	991M	10.44B	9.46B	10.1B
Net Debt	302M	153M	577M	9.76B	8.41B	7.91B
Debt / Equity	0.02x	0.02x	0.04x	0.63x	0.57x	0.62x
Debt / EBITDA	0.55x	0.26x	0.52x	4.94x	4.10x	4.21x
Net Debt / EBITDA	0.26x	0.08x	0.30x	4.62x	3.65x	3.29x
Interest Coverage	34.50x	106.53x	102.38x	6.56x	4.82x	5.60x
Total Equity+	27.41B	26.22B	26.48B	16.46B	16.73B	16.22B
Equity Growth %	-	-0.04%	0.01%	-0.38%	0.02%	-0.03%
Book Value per Share	5.94	5.68	5.73	3.56	3.61	3.54
Total Shareholders' Equity	27.32B	26.11B	26.36B	16.33B	16.61B	16.17B
Common Stock	1M	1M	1M	92M	92M	91M
Retained Earnings	5.11B	37.76B	37.99B	26.73B	27.47B	27.27B
Treasury Stock	0	0	0	0	0	-116M
Accumulated OCI	1.37B	-11.65B	-11.63B	1.2B	-10.96B	0
Minority Interest	91M	111M	125M	126M	123M	58M

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	786M	1.41B	1.36B	2.06B	2.1B	2.3B
Operating CF Margin %	0.09%	0.14%	0.14%	0.19%	0.19%	0.2%
Operating CF Growth %	-	0.79%	-0.04%	0.52%	0.02%	0.1%
Net Income	687M	1.18B	1.39B	1.12B	1.05B	1.44B
Depreciation & Amortization	260M	305M	268M	287M	309M	324M
Stock-Based Compensation	58M	63M	59M	78M	88M	102M
Deferred Taxes	199M	0	197M	62M	0	0
Other Non-Cash Items	43M	-157M	-406M	336M	711M	385M
Working Capital Changes	-461M	15M	-152M	181M	-219M	48M
Change in Receivables	-57M	18M	14M	-85M	38M	-312M
Change in Inventory	232M	130M	-17M	-292M	-131M	216M
Change in Payables	-256M	140M	41M	387M	112M	0
Cash from Investing+	291M	1.03B	-33M	-8.78B	-134M	528M
Capital Expenditures	-243M	-318M	-298M	-328M	-234M	-250M
CapEx % of Revenue	0.03%	0.03%	0.03%	0.03%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	142M	853M	165M	-9.16B	171M	778M
Cash from Financing+	-925M	-2.44B	-1.24B	6.91B	-1.57B	-1.54B
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	-1.15B	-2.37B	-1.15B	-2.68B	-388M	-570M
Share Repurchases	-	-	-	-	-	-
Other Financing	226M	-94M	-96M	107M	-589M	-1.44B
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	543M	1.09B	1.06B	1.74B	1.76B	2.05B
FCF Margin %	0.06%	0.11%	0.11%	0.16%	0.16%	0.18%
FCF Growth %	-	1.01%	-0.03%	0.64%	0.02%	0.16%
FCF per Share	0.12	0.24	0.23	0.38	0.38	0.45
FCF Conversion (FCF/Net Income)	1.20x	1.23x	0.98x	1.95x	2.00x	1.60x
Interest Paid	0	0	0	0	0	360M
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	2.39%	4.27%	5.27%	4.94%	6.32%	8.75%
Return on Invested Capital (ROIC)	2.43%	4.43%	4.6%	5.14%	5.83%	6.72%
Gross Margin	56.63%	59.75%	62.34%	60.57%	61.59%	61.85%
Net Margin	7.72%	11.58%	14.56%	9.76%	9.28%	12.84%
Debt / Equity	0.02x	0.02x	0.04x	0.63x	0.57x	0.62x
Interest Coverage	34.50x	106.53x	102.38x	6.56x	4.82x	5.60x
FCF Conversion	1.20x	1.23x	0.98x	1.95x	2.00x	1.60x
Revenue Growth	-	16.65%	-3.51%	13.76%	4.09%	-0.61%

Revenue by Segment

	2022
Respiratory Health	1.58B
Respiratory Health Growth	-

Revenue by Geography

	2022
World	5.91B
World Growth	-
UNITED STATES	3.69B
UNITED STATES Growth	-
CHINA	907M
CHINA Growth	-

Frequently Asked Questions

Valuation & Price

Haleon plc (HLN) has a price-to-earnings (P/E) ratio of 30.5x. This suggests investors expect higher future growth.

Growth & Financials

Haleon plc (HLN) reported $22.28B in revenue for fiscal year 2024. This represents a 163% increase from $8.48B in 2019.

Haleon plc (HLN) saw revenue decline by 0.6% over the past year.

Yes, Haleon plc (HLN) is profitable, generating $2.61B in net income for fiscal year 2024 (12.8% net margin).

Dividend & Returns

Yes, Haleon plc (HLN) pays a dividend with a yield of 1.27%. This makes it attractive for income-focused investors.

Haleon plc (HLN) has a return on equity (ROE) of 8.8%. This is below average, suggesting room for improvement.

Haleon plc (HLN) generated $931.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

← Back to Screener

US Stock Screener

...

Haleon plc (HLN) 10-Year Financial Performance & Capital Metrics

HLN • • Industrial / General

HealthcareSpecialty & Generic PharmaConsumer HealthcareOTC Medications

Revenue $11.23B -0.6%
EBITDA $2.4B +4.2%
Net Income $1.44B +37.5%
EPS (Diluted) 0.32 +33.3%
Gross Margin 61.85% +0.4%
EBITDA Margin 21.38% +4.8%
Operating Margin 19.64% +11.2%
Net Margin 12.84% +38.3%
ROE 8.75% +38.4%
ROIC 6.72% +15.2%
Debt/Equity 0.62 +10.2%
Interest Coverage 5.60 +16.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y profit CAGR of 17.1%
✓FCF machine: 18.3% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Healthy 5Y average net margin of 11.6%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y5.78%

3Y5.58%

TTM62.05%

Profit (Net Income) CAGR

10Y-

5Y17.1%

3Y1.23%

TTM49.48%

EPS CAGR

10Y-

5Y17.98%

3Y2.17%

TTM52.45%

ROCE

10Y Avg5.63%

5Y Avg6.19%

3Y Avg6.77%

Latest7.62%

Peer Comparison

OTC Medications

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
HLNHaleon plc	43.51B	9.77	30.53	-0.61%	11.72%	16.31%	4.71%	0.62
UPCUniverse Pharmaceuticals Inc.	2.59M	4.59	-0.00	-28.74%	-37.94%	-31.64%		0.18
PRPHProPhase Labs, Inc.	711.94K	0.17	-0.07	-84.75%	-38.72%	-6.08%		3.34
COSMCosmos Health Inc.	20.24M	0.54	-0.46	1.97%	-31.01%	-80.15%		0.48
PRGOPerrigo Company plc	2.09B	15.17	-12.14	-6.06%	-1.21%	-1.17%	11.72%	0.84

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	8.48B	9.89B	9.54B	10.86B	11.3B	11.23B
Revenue Growth %	-	0.17%	-0.04%	0.14%	0.04%	-0.01%
Cost of Goods Sold+	3.68B	3.98B	3.6B	4.28B	4.34B	4.29B
COGS % of Revenue	0.43%	0.4%	0.38%	0.39%	0.38%	0.38%
Gross Profit+	4.8B	5.91B	5.95B	6.58B	6.96B	6.95B
Gross Margin %	0.57%	0.6%	0.62%	0.61%	0.62%	0.62%
Gross Profit Growth %	-	0.23%	0.01%	0.11%	0.06%	-0%
Operating Expenses+	3.9B	4.31B	4.31B	4.75B	4.96B	4.74B
OpEx % of Revenue	0.46%	0.44%	0.45%	0.44%	0.44%	0.42%
Selling, General & Admin	3.6B	4.22B	3.79B	4.04B	4.29B	4.33B
SG&A % of Revenue	0.42%	0.43%	0.4%	0.37%	0.38%	0.39%
Research & Development	292M	304M	257M	300M	311M	298M
R&D % of Revenue	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%
Other Operating Expenses	17M	-212M	262M	415M	366M	111M
Operating Income+	897M	1.6B	1.64B	1.82B	2B	2.21B
Operating Margin %	0.11%	0.16%	0.17%	0.17%	0.18%	0.2%
Operating Income Growth %	-	0.78%	0.03%	0.11%	0.09%	0.11%
EBITDA+	1.16B	1.9B	1.91B	2.11B	2.31B	2.4B
EBITDA Margin %	0.14%	0.19%	0.2%	0.19%	0.2%	0.21%
EBITDA Growth %	-	0.64%	0%	0.11%	0.09%	0.04%
D&A (Non-Cash Add-back)	260M	305M	268M	287M	309M	196M
EBIT	912M	1.61B	1.94B	1.9B	2.04B	2.32B
Net Interest Income+	-10M	-13M	-3M	-220M	-400M	-339M
Interest Income	24M	0	13M	62M	14M	55M
Interest Expense	26M	15M	16M	278M	414M	394M
Other Income/Expense	-11M	-7M	-2M	-207M	-368M	-296M
Pretax Income+	886M	1.59B	1.64B	1.62B	1.63B	1.91B
Pretax Margin %	0.1%	0.16%	0.17%	0.15%	0.14%	0.17%
Income Tax+	199M	410M	197M	499M	517M	435M
Effective Tax Rate %	0.74%	0.72%	0.85%	0.66%	0.64%	0.75%
Net Income+	655M	1.15B	1.39B	1.06B	1.05B	1.44B
Net Margin %	0.08%	0.12%	0.15%	0.1%	0.09%	0.13%
Net Income Growth %	-	0.75%	0.21%	-0.24%	-0.01%	0.37%
Net Income (Continuing)	687M	1.18B	1.44B	1.12B	1.11B	1.48B
Discontinued Operations	0	0	0	0	0	0
Minority Interest	91M	111M	125M	126M	123M	58M
EPS (Diluted)+	0.14	0.24	0.30	0.24	0.24	0.32
EPS Growth %	-	0.71%	0.25%	-0.2%	0%	0.33%
EPS (Basic)	0.14	0.24	0.30	0.24	0.24	0.32
Diluted Shares Outstanding	4.62B	4.62B	4.62B	4.62B	4.63B	4.59B
Basic Shares Outstanding	4.62B	4.62B	4.62B	4.62B	4.63B	4.57B
Dividend Payout Ratio	1.76%	2.07%	0.83%	2.53%	0.37%	0.4%

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.81B	5.01B	5.25B	4.06B	4.82B	5.72B
Cash & Short-Term Investments	340M	334M	414M	684M	1.04B	2.25B
Cash Only	340M	334M	414M	684M	1.04B	2.19B
Short-Term Investments	0	0	0	0	0	55M
Accounts Receivable	3.99B	1.35B	3.83B	1.49B	1.35B	1.9B
Days Sales Outstanding	171.91	49.74	146.27	49.99	43.66	61.87
Inventory	1.21B	949M	951M	1.35B	1.41B	1.19B
Days Inventory Outstanding	120.18	86.99	96.55	114.93	118.39	101.37
Other Current Assets	237M	2.32B	5M	434M	907M	223M
Total Non-Current Assets+	29.9B	29.12B	29.2B	30.76B	29.24B	28.6B
Property, Plant & Equipment	1.62B	1.6B	1.66B	1.9B	1.9B	1.92B
Fixed Asset Turnover	5.23x	6.17x	5.74x	5.72x	5.94x	5.85x
Goodwill	8.17B	8.27B	8.25B	8.4B	8.32B	8.2B
Intangible Assets	19.84B	18.95B	18.95B	20.04B	18.54B	18.01B
Long-Term Investments	3M	0	23M	44M	65M	82M
Other Non-Current Assets	10M	51M	8M	157M	415M	383M
Total Assets+	35.71B	34.13B	34.45B	34.81B	34.05B	34.31B
Asset Turnover	0.24x	0.29x	0.28x	0.31x	0.33x	0.33x
Asset Growth %	-	-0.04%	0.01%	0.01%	-0.02%	0.01%
Total Current Liabilities+	4.27B	4.01B	4.24B	4.37B	4.64B	5.81B
Accounts Payable	1.9B	1.83B	1.58B	1.83B	1.85B	1.97B
Days Payables Outstanding	188.36	167.47	160.32	156.45	155.97	168.06
Short-Term Debt	481M	348M	874M	393M	608M	1.44B
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0
Other Current Liabilities	913M	958M	1.43B	1.61B	1.57B	693M
Current Ratio	1.36x	1.25x	1.24x	0.93x	1.04x	0.98x
Quick Ratio	1.08x	1.01x	1.01x	0.62x	0.73x	0.78x
Cash Conversion Cycle	103.73	-30.74	82.51	8.46	6.08	-4.83
Total Non-Current Liabilities+	4.03B	3.89B	3.73B	13.99B	12.69B	12.28B
Long-Term Debt	0	0	0	9.89B	8.71B	8.54B
Capital Lease Obligations	121M	105M	87M	117M	89M	73M
Deferred Tax Liabilities	3.51B	0	3.36B	3.6B	3.49B	3.35B
Other Non-Current Liabilities	0	3.79B	0	384M	424M	311M
Total Liabilities	8.3B	7.91B	7.97B	18.36B	17.33B	18.09B
Total Debt+	642M	487M	991M	10.44B	9.46B	10.1B
Net Debt	302M	153M	577M	9.76B	8.41B	7.91B
Debt / Equity	0.02x	0.02x	0.04x	0.63x	0.57x	0.62x
Debt / EBITDA	0.55x	0.26x	0.52x	4.94x	4.10x	4.21x
Net Debt / EBITDA	0.26x	0.08x	0.30x	4.62x	3.65x	3.29x
Interest Coverage	34.50x	106.53x	102.38x	6.56x	4.82x	5.60x
Total Equity+	27.41B	26.22B	26.48B	16.46B	16.73B	16.22B
Equity Growth %	-	-0.04%	0.01%	-0.38%	0.02%	-0.03%
Book Value per Share	5.94	5.68	5.73	3.56	3.61	3.54
Total Shareholders' Equity	27.32B	26.11B	26.36B	16.33B	16.61B	16.17B
Common Stock	1M	1M	1M	92M	92M	91M
Retained Earnings	5.11B	37.76B	37.99B	26.73B	27.47B	27.27B
Treasury Stock	0	0	0	0	0	-116M
Accumulated OCI	1.37B	-11.65B	-11.63B	1.2B	-10.96B	0
Minority Interest	91M	111M	125M	126M	123M	58M

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	786M	1.41B	1.36B	2.06B	2.1B	2.3B
Operating CF Margin %	0.09%	0.14%	0.14%	0.19%	0.19%	0.2%
Operating CF Growth %	-	0.79%	-0.04%	0.52%	0.02%	0.1%
Net Income	687M	1.18B	1.39B	1.12B	1.05B	1.44B
Depreciation & Amortization	260M	305M	268M	287M	309M	324M
Stock-Based Compensation	58M	63M	59M	78M	88M	102M
Deferred Taxes	199M	0	197M	62M	0	0
Other Non-Cash Items	43M	-157M	-406M	336M	711M	385M
Working Capital Changes	-461M	15M	-152M	181M	-219M	48M
Change in Receivables	-57M	18M	14M	-85M	38M	-312M
Change in Inventory	232M	130M	-17M	-292M	-131M	216M
Change in Payables	-256M	140M	41M	387M	112M	0
Cash from Investing+	291M	1.03B	-33M	-8.78B	-134M	528M
Capital Expenditures	-243M	-318M	-298M	-328M	-234M	-250M
CapEx % of Revenue	0.03%	0.03%	0.03%	0.03%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	142M	853M	165M	-9.16B	171M	778M
Cash from Financing+	-925M	-2.44B	-1.24B	6.91B	-1.57B	-1.54B
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	-1.15B	-2.37B	-1.15B	-2.68B	-388M	-570M
Share Repurchases	-	-	-	-	-	-
Other Financing	226M	-94M	-96M	107M	-589M	-1.44B
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	543M	1.09B	1.06B	1.74B	1.76B	2.05B
FCF Margin %	0.06%	0.11%	0.11%	0.16%	0.16%	0.18%
FCF Growth %	-	1.01%	-0.03%	0.64%	0.02%	0.16%
FCF per Share	0.12	0.24	0.23	0.38	0.38	0.45
FCF Conversion (FCF/Net Income)	1.20x	1.23x	0.98x	1.95x	2.00x	1.60x
Interest Paid	0	0	0	0	0	360M
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	2.39%	4.27%	5.27%	4.94%	6.32%	8.75%
Return on Invested Capital (ROIC)	2.43%	4.43%	4.6%	5.14%	5.83%	6.72%
Gross Margin	56.63%	59.75%	62.34%	60.57%	61.59%	61.85%
Net Margin	7.72%	11.58%	14.56%	9.76%	9.28%	12.84%
Debt / Equity	0.02x	0.02x	0.04x	0.63x	0.57x	0.62x
Interest Coverage	34.50x	106.53x	102.38x	6.56x	4.82x	5.60x
FCF Conversion	1.20x	1.23x	0.98x	1.95x	2.00x	1.60x
Revenue Growth	-	16.65%	-3.51%	13.76%	4.09%	-0.61%

Revenue by Segment

	2022
Respiratory Health	1.58B
Respiratory Health Growth	-

Revenue by Geography

	2022
World	5.91B
World Growth	-
UNITED STATES	3.69B
UNITED STATES Growth	-
CHINA	907M
CHINA Growth	-

Frequently Asked Questions

Valuation & Price

Haleon plc (HLN) has a price-to-earnings (P/E) ratio of 30.5x. This suggests investors expect higher future growth.

Growth & Financials

Haleon plc (HLN) reported $22.28B in revenue for fiscal year 2024. This represents a 163% increase from $8.48B in 2019.

Haleon plc (HLN) saw revenue decline by 0.6% over the past year.

Yes, Haleon plc (HLN) is profitable, generating $2.61B in net income for fiscal year 2024 (12.8% net margin).

Dividend & Returns

Yes, Haleon plc (HLN) pays a dividend with a yield of 1.27%. This makes it attractive for income-focused investors.

Haleon plc (HLN) has a return on equity (ROE) of 8.8%. This is below average, suggesting room for improvement.

Haleon plc (HLN) generated $931.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.